HEPATIC CLEARANCE OF APOLIPOPROTEIN B

载脂蛋白 B 的肝脏清除率

基本信息

  • 批准号:
    3340889
  • 负责人:
  • 金额:
    $ 9.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1983
  • 资助国家:
    美国
  • 起止时间:
    1983-04-01 至 1986-03-31
  • 项目状态:
    已结题

项目摘要

Work in my laboratory first directly demonstrated the rapid hepatic clearance of apolipoprotein B of lower molecular weight (apo B1) from rat plasma compared to apolipoprotein B of higher molecular weight (apo Bh). The use of SDS-gel filtration column chromatography enabled a direct comparison of apo B1 label in whole serum to liver homogenates, allowing a direct calculation of hepatic apo B1 clearance rates. In rats apo B1 represents a secretory protein of liver and intestine as opposed to apo Bh which is an hepatic secretory protein. Apo Bh containing secretory lipoproteins (Lps) undergo progressive delipidation and eventually apo Bh constitutes the major apo B protein of LDL. Recent experiments described in this proposed provide an explanation. The liver has a binding site for apo B1 enriched Lps which allows discrimination from apo Bh containing Lps. Hepatic recognition requires prior lipase interaction with Lps. Once bound the apo B1 enriched Lps are internalized and degraded. The apo Bh-Lps remain in the plasma in LDL with a slow catabolic rate. I propose studies using isolated liver perfusion to characterize the apo B1 hepatic binding site. These experiments will involve study of characterized Lp particles which vary in apoprotein composition. Using apo B1-Lps the binding site will be characterized in terms of affinity, saturation, turnover, apoprotein specificity and lysosomal interaction. A calculation of receptor number will be made and it will be determined whether dietary or metabolic state alters the number. Using particles of mixed composition, favorable apoprotein composition for hepatic clearance of Lps will be determined with particular interest in the role of surface protein (apo C, apo E and apo A-1) on binding of apo B1-Lps. Considering the evidence that apo E may mediate Lp interaction with liver, a reasonable hypothesis is that apo E increases the hepatic sinusoidal concentration of Lps for action as a substrate for sinusoidal lipases. Apo B1 recognition may occur only following lipase modification and apo B1 hepatic clearance would, therefore, be facilitated by apo E present on the Lp. Particle composition of apo B1-Lps is seen as critical to their eventual hepatic catabolism. These studies assume importance because of the relationship of apo B-Lps, especially IDL and LDL, in development and progression of human atherosclerosis.
我实验室的工作首先直接证明了肝细胞的快速生长

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHARLES Edward SPARKS其他文献

CHARLES Edward SPARKS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHARLES Edward SPARKS', 18)}}的其他基金

NUTRITIONAL EFFECTS OF SUGARS ON LIVER LIPIDS
糖对肝脂的营养影响
  • 批准号:
    3354676
  • 财政年份:
    1988
  • 资助金额:
    $ 9.56万
  • 项目类别:
NUTRITIONAL EFFECTS OF SUGARS ON LIVER LIPIDS
糖对肝脂的营养影响
  • 批准号:
    3354678
  • 财政年份:
    1988
  • 资助金额:
    $ 9.56万
  • 项目类别:
NUTRITIONAL EFFECTS OF SUGARS ON LIVER LIPIDS
糖对肝脂的营养影响
  • 批准号:
    3354677
  • 财政年份:
    1988
  • 资助金额:
    $ 9.56万
  • 项目类别:
HEPATIC METABOLISM OF APOLIPOPROTEIN B
载脂蛋白 B 的肝脏代谢
  • 批准号:
    2216516
  • 财政年份:
    1983
  • 资助金额:
    $ 9.56万
  • 项目类别:
HEPATIC METABOLISM OF APOLIPOPROTEIN B
载脂蛋白 B 的肝脏代谢
  • 批准号:
    3340885
  • 财政年份:
    1983
  • 资助金额:
    $ 9.56万
  • 项目类别:
HEPATIC CLEARANCE OF APOLIPOPROTEIN B
载脂蛋白 B 的肝脏清除率
  • 批准号:
    3340883
  • 财政年份:
    1983
  • 资助金额:
    $ 9.56万
  • 项目类别:
HEPATIC CLEARANCE OF APOLIPOPROTEIN B
载脂蛋白 B 的肝脏清除率
  • 批准号:
    3340890
  • 财政年份:
    1983
  • 资助金额:
    $ 9.56万
  • 项目类别:
HEPATIC METABOLISM OF APOLIPOPROTEIN B
载脂蛋白 B 的肝脏代谢
  • 批准号:
    2028118
  • 财政年份:
    1983
  • 资助金额:
    $ 9.56万
  • 项目类别:
HEPATIC METABOLISM OF APOLIPOPROTEIN B
载脂蛋白 B 的肝脏代谢
  • 批准号:
    2216514
  • 财政年份:
    1983
  • 资助金额:
    $ 9.56万
  • 项目类别:
HEPATIC CLEARANCE OF APOLIPOPROTEIN B
载脂蛋白 B 的肝脏清除率
  • 批准号:
    3340891
  • 财政年份:
    1983
  • 资助金额:
    $ 9.56万
  • 项目类别:

相似国自然基金

PDLIM3-Cholesterol-SMO轴调控SHH通路激活及其在髓母细胞瘤中的功能研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
以促内涵体逃逸聚合物PEG-P[Asp(TEP)]-cholesterol为载体构建双级脑靶向基因传递系统沉默BACE1基因的研究
  • 批准号:
    81302714
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Reducing the production of toxic Abeta peptides in Alzheimer's disease by mutating the APP cholesterol-binding site: a new therapeutic strategy?
通过突变 APP 胆固醇结合位点来减少阿尔茨海默病中有毒 Abeta 肽的产生:一种新的治疗策略?
  • 批准号:
    MR/Y013859/1
  • 财政年份:
    2023
  • 资助金额:
    $ 9.56万
  • 项目类别:
    Research Grant
The role of cholesterol biosynthesis in CAF for tumorigenesis
CAF 中胆固醇生物合成对肿瘤发生的作用
  • 批准号:
    23K14585
  • 财政年份:
    2023
  • 资助金额:
    $ 9.56万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Application of New Tools for Probing the Roles of Sphingolipids and Cholesterol in Influenza Virus Infection
应用新工具探索鞘脂和胆固醇在流感病毒感染中的作用
  • 批准号:
    10678459
  • 财政年份:
    2023
  • 资助金额:
    $ 9.56万
  • 项目类别:
A novel role of cholesterol and SR-BI in adipocyte biology
胆固醇和 SR-BI 在脂肪细胞生物学中的新作用
  • 批准号:
    10733720
  • 财政年份:
    2023
  • 资助金额:
    $ 9.56万
  • 项目类别:
Cholesterol homeostasis in the vertebrate retina
脊椎动物视网膜中的胆固醇稳态
  • 批准号:
    10580969
  • 财政年份:
    2023
  • 资助金额:
    $ 9.56万
  • 项目类别:
Cholesterol-lowering drugs for treatment of pancreatitis: validation of a clinically significant novel therapeutic target and approach
用于治疗胰腺炎的降胆固醇药物:验证具有临床意义的新型治疗靶点和方法
  • 批准号:
    10585773
  • 财政年份:
    2023
  • 资助金额:
    $ 9.56万
  • 项目类别:
Disturbed Crosstalk between Cholesterol Homeostasis and Inflammation Resolution in NASH
NASH 中胆固醇稳态与炎症消退之间的干扰串扰
  • 批准号:
    10568478
  • 财政年份:
    2023
  • 资助金额:
    $ 9.56万
  • 项目类别:
Understanding of cholesterol transporter mechanisms via HS-AFM and computational modeling
通过 HS-AFM 和计算模型了解胆固醇转运机制
  • 批准号:
    22KF0153
  • 财政年份:
    2023
  • 资助金额:
    $ 9.56万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Healthy Heart Remnant Cholesterol Tackles Diabetes in Youth
健康的心脏残余胆固醇可治疗青少年糖尿病
  • 批准号:
    499350
  • 财政年份:
    2023
  • 资助金额:
    $ 9.56万
  • 项目类别:
    Salary Programs
Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer
以前列腺癌为模型的强化降胆固醇干预和抗肿瘤免疫
  • 批准号:
    10802975
  • 财政年份:
    2023
  • 资助金额:
    $ 9.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了